Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197853 | 0.85 | EPHX2 (0.43) | EPHX2AHRALDH1A1HPGDMCHR1 | |
| SCHEMBL13197987 | 0.85 | MCHR1 (0.44) | EPHX2ALDH1A1EPHX1MCHR1 | |
| SCHEMBL13197837 | 0.85 | SMN1; SMN2 (0.48) | EPHX2AHRALDH1A1HPGD | |
| SCHEMBL13197846 | 0.85 | EPHX2 (0.42) | EPHX2AHRALDH1A1HPGDMCHR1 | |
| SCHEMBL1594683 | 0.85 | EPHX2 (0.50) | EPHX2ALDH1A1EPHX1 | |
| SCHEMBL13197831 | 0.84 | EPHX2 (0.42) | EPHX2AHRALDH1A1HPGDMCHR1 | |
| SCHEMBL13197816 | 0.84 | EPHX2 (0.45) | EPHX2ALDH1A1EPHX1MCHR1 | |
| SCHEMBL13197935 | 0.84 | MCHR1 (0.43) | EPHX2ALDH1A1EPHX1MCHR1 | |
| SCHEMBL14793970 | 0.83 | EPHX2 (0.49) | EPHX2ALDH1A1EPHX1MCHR1 | |
| SCHEMBL2569969 | 0.83 | MCHR1 (0.44) | EPHX2ALDH1A1EPHX1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | EPHX2 3922/4885AHR 3830/4885ALDH1A1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.